Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Aerogen  (Stock symbol: AEGN ) Acquired by Nektar Therapeutics (2005 $ 32,000,000)

2071 Stierlin Court
Mountain View, CA 94043
Website Company Summary Management Team

Outside board: (May no longer be on the board) Robert L. Roe (Corcept Therapeutics President) Richard T. Daly (Visible Genetics Former CEO) Jean-Jacques Bienaime (Sangstat) Bernard Collins (Boston Scientific);  Phyllis Gardner (Stanford Medical Center);  Philip M. Young (U.S. Venture Partners)

Business description: Aerogen, an emerging specialty pharmaceutical company, is developing inhaler and nebulizer products, based on its proprietary aerosol generator technology, for the treatment of respiratory disorders in the home and hospital markets. Aerogen is also applying its technology to develop products in collaboration with pharmaceutical and biotechnology companies for the treatment of respiratory and other disorders, including diabetes. Aerogen now markets two Aeroneb nebulizer systems, one optimized for professional use in the hospital and the other for home use. Aerogen Aerodose inhaler products, in development, have advanced into Phase 2 clinical trials. Additional products are in the feasibility and pre-clinical stages of development.

Rounds: 3
Capital raised: 32.2M
Ownership: Acquired by Nektar Therapeutics (2005 $ 32,000,000)
Stock Symbol: AEGN

Last Tweets


Last Mentions

Record updated: Aug 2005
Sector: Medical
Year Founded: 1994
Headcount: 76-100 as of Jan 2004
Rounds: 3
Capital Raised: 32.2M
Ownership: Acquired by Nektar Therapeutics (2005 $ 32,000,000)
Stock Symbol: AEGN